Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Bayer : drives awareness and scientific discussion around lungworm -- Greater need to better understand the prevalence of lungworm in European countries / Scientific experts discuss prevention, infection, and persistence of lungworm

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 12:25pm CEST

Copenhagen (Denmark), October 5, 2017- Snails can explore the length of an average British garden in a single night, reaching a top speed of one meter per hour. They may seem like harmless creatures at first sight, but snails and slugs are quickly becoming a strong threat to the health and well-being of dogs. More and more dog owners have recently become aware of a disease which has been diagnosed more frequently over the last years throughout many European countries - Angiostrongylus vasorum (Lungworm/ French Heartworm).

Lungworm, or French Heartworm, is a disease spread by parasitic nematodes that can cause angiostrongylosis, a serious illness in dogs and other canine species. The parasite can be carried by slugs and snails and infect animals. The disease has not been shown to transmit to humans and is not considered a zoonotic disease. However, it was a topic of intense discussion and debate at the 42World Small Animal Veterinary Association (WSAVA) Congress in Copenhagen, Denmark.

The WSAVA hosts a veterinary congress once a year for companion animal veterinarians from across the globe. It is an internationally recognized veterinary congress with a scientific program.

Bayer Animal Health organized a continuing professional development for veterinarians and key opinion leaders entitled 'NEW UPDATES ON ANGIOSTRONGYLUS VASORUM IN EUROPE'. A panel of veterinary parasitology experts shared some insights on this topic.

Dr. Eric Morgan, MA, VetMB, PhD, BA, MRCVS UK, University of Bristol, Veterinary Parasitology and Ecology
'Lungworm infection used to be a rare disease in few European countries. However, we have had more cases recently in many European countriesso it is on the increase. For the UK and Germany there is now evidence that it is spreading. Spread of the disease is likely through infected dogs and foxes and via slugs and snails.'

Dr. Roland Schaper, Dr. med. vet, Bayer Animal Health GmbH, Global Veterinary Scientific Affairs Manager, Germany
'Treatment of an existing
A. vasoruminfection should be the last resort, due to the severity of the disease. Prevention of this potentially fatal disease with regular treatment is a good approach. But the best approach to avoid any parasite development completely is true infection prevention.'

While the lungworm is recognized as a major threat in the United Kingdom and the Nordics, it still seems to be underestimated in other European countries such as France, Germany and the Benelux. For the United Kingdom and Germany there is new evidence that it is spreading.

'This also demonstrates the importance of continuous training for veterinarians,' says Dr. Markus Edingloh, Global Head of Veterinary Scientific Affairs at Bayer Animal Health. 'Therefore, Bayer Animal Health is proud to support veterinarians with continuing professional development about the latest information and techniques. We want to emphasize the importance of fighting Angiostrongylus vasorumand draw attention to the fact that prevention plays an essential role in keeping our animals healthy.'

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.

Bayer AG published this content on 05 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 October 2017 10:24:06 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
05:40pBAYER AKTIENGESELLSCHAFT : Release according to Article 41 of the WpHG [the Germ..
12:12pBAYER : issues new bonds with a volume of 15 billion U.S. dollars
06/18BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
06/15BAYER : Japan suspends sale of Canadian wheat after GMO wheat found in Alberta
06/15BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
06/15BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
06/15BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
06/14BAYER : Recent Findings from F. Kanefendt and Co-Authors Yields New Data on Phar..
06/14Bayer begins Rs 1.3K cr offer to buy stake in Monsanto
06/14BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
More news
News from SeekingAlpha
07:28aCan-Fite up 14% premarket on encouraging mid-stage Namodenoson data 
06/13Biotech industry group criticized for party featuring topless dancers 
06/11Merck KGaA's tepotinib successful two mid-stage liver cancer studies 
06/093 THINGS IN BIOTECH, JUNE 8 : Ascend Ye PARP Inhibitors 
06/08Risk Aversion Returns Ahead Of Tense G7 Summit; China's US Trade Surplus Jump.. 
Financials (€)
Sales 2018 35 204 M
EBIT 2018 7 149 M
Net income 2018 5 138 M
Debt 2018 6 671 M
Yield 2018 2,87%
P/E ratio 2018 17,54
P/E ratio 2019 15,66
EV / Sales 2018 2,83x
EV / Sales 2019 2,67x
Capitalization 93 008 M
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 116 €
Spread / Average Target 18%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-2.22%108 112
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168